The German competence network 'acute and chronic leukemias'

Leukemia

Volumn 18, Issue 4, 2004, Pages 665-669

  Hehlmann, R ^a   Berger, U ^a   Aul, C ^a   Büchner, Th ^a   Dohner H ^a   Ehninger, G ^a   Ganser, A ^a   Gokbuget N ^a   Hoelzer, D ^a   Uberla K ^a   Gassmann, W ^a   Ludwig, W D ^a   Rieder, H ^a   Kneba, M ^a   Hochhaus, A ^a   Reiter, A ^a   Hiddemann, W ^a   Ottmann, O G ^a   Germing, U ^a   Adelhard, K ^a   Dugas, M ^a   Dirschedl, P ^a   Messerer, D ^a   Bohme A ^a   Harrison Neu, E ^a   Grieshammer, M ^a   Kienast, J ^a   Kolb, H J ^a   Ho, A D ^a   Hallek, M ^a   Neubauer, A ^a   Schlegelberger, B ^a   Neiderwieser, D ^a   Heil, G ^a   Muller T ^a   Hasford, J ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; HEMOPOIETIC GROWTH FACTOR; IMATINIB; MYELOBLASTIN; PEGINTERFERON ALPHA2A;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPETENCE; COST EFFECTIVENESS ANALYSIS; EDITORIAL; GERMANY; HUMAN; INFECTION COMPLICATION; INFORMATION PROCESSING; MEDICAL SPECIALIST; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

EID: 4744373887     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403317     Document Type: Editorial

References (18)

1. Förderrichtlinien des BMBF zur Einrichtung von Kompetenznetzwerken für die Medizin (MedNet) vom 15.09.1997. DLR-PT Gesundheitsforschung 1997.
2. th Framework Programme of the EU. Thematic call in the area 'Life science, genomics and biotechnology for health'. Cordis 2002.
3. Zerhouni E. The NIH roadmap. Science 2003; 302: 63-72.
4. Ludwig WD, Haferlach T, Schoch C. Classification of acute leukemias: perspective 1. In: Pui CH (ed) Treatment of Acute Leukemias: New Directions for Clinical Research. Totowa: Humana Press, 2003, 3-41.
5. Dugas M, Schoch C, Schnittger S, Haferlach T, Hiddemann W, Messerer D et al. A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping. Leukemia 2001; 15: 1805-1810.
6. Fröhling S, Skelin S, Scholl C, Schlenk RF, Döhner H, Acute Myeloid Leukemia Study Group Ulen et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 2002; 20: 2480-2485.
7. Schoch C, Schnittger S, Bursch S, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53-59.
8. Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T et al. Molecular monitoring of response to imatinib (Glivec(R)) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003; 17: 1687-1694.
9. Müller MC, Gattermann N, Lahaye T, Deininger MWN, Frühauf S, Neubauer A et al. Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia 2003; 17: 2392-2400.
10. Hehlmann R, Berger U, Reiter A, Behringer J, Hochhaus A. Midterm Report and Follow-up Proposals BMBF. DLR-PT Gesundheitsforschung, Bonn-Bad Godesberg, 2002.
11. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259-264.
12. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
13. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
14. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380.
15. Hoelzer D, Gökbuget N, Digel W, Faak Th, Kneba M, Reutzel R et al, for the GMALL Study Group. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for ALL. Blood 2002; 99: 4379-4385.
16. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T et al. Double induction strategy for acute myeloid leukemia: The effect of high dose cytarabine with mithoanthrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanin: A randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116-4124.
17. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, the German CML Study Group et al. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): prolongation of survival by the combination of interferon α and hydroxyurea. Leukemia 2003; 17: 1529-1537.
18. Berger U, Engelich G, Pfirrmann M, Hochhaus A, Reiter A, Metzgeroth G et al. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia 2003; 17: 1820-1826.